Cerebral protection developer Claret Medical recently won FDA de novo clearance for its Sentinel device designed to trap blood clots and prevent stroke during heart valve replacement procedures. The Sentinel uses a pair of filters, 1 in the brachiocephalic artery another in the left common carotid artery, to trap debris released during transcatheter aortic valve replacement that could cause […]
Neurological
Welcome to MassDevice's Neurological Hub, your resource for the latest news in the neurological device space. Stay informed about the innovations and business news shaping the neurological industry.
🧠 Narrow your focus with these categories:
Neuromodulation/Neurostimulation | Bioelectronic Medicine | Pain Management | Brain-Computer Interfaces
Here are the top neurological device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ 7 brain-computer interface companies you need to know
+ Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research
+ Natalizumab and PML: The complex dance of benefit and risk for MS
Latest Neurological News
Novocure launches Optune, chemotherapy combo trial for glioblastoma
Novocure (NSDQ:NVCR) said today that the 1st patient was enrolled in a Phase II pilot trial evaluating Optune with bevacizumab, a chemotherapy, for patients with refractory recurrent glioblastoma. In recurrent GBM, Optune and bevacizumab are approved as monotherapies. Novocure’s consortium study is slated to evaluate the efficacy and safety of the Optune-chemo combo in patients […]
Medtronic wins Health Canada nod for SureTune3 DBS software
Medtronic (NYSE:MDT) said today it won Health Canada approval for its SureTune3 software designed for programming deep brain stimulation therapy. The Fridley, Minn.-based company said the DBS Therapy system is licensed by Health Canada for treating diseases such as Parkinsons and for treating symptoms such as tremors through the application of mild electrical stimulation to precise targets in […]
Living Cell Technologies NTCell meets primary endpoint in Phase I/IIa Parkinson’s trial
Living Cell Technologies (ASX:LCT) touted data today showing its NTCell cell therapy is safe 130 weeks after treatment in a Phase I/IIa Parkinson’s trial. The study’s primary endpoint was safety. The trial, which enrolled and treated 4 patients, involved implanting 40 NTCell capsules into 1 side of the brain. The company reported that treatment with […]
Inhaled Parkinson’s treatment improves motor function in Phase III
Shares in Acorda Therapeutics (NSDQ:ACOR) jumped this morning after the company reported that its inhaled Parkinson’s drug significantly improved motor function in a Phase III trial. The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms. The Phase III Span-Pd trial enrolled 339 patients with […]
Cingulate moves controlled-release ADHD drug to human testing
Cingulate Therapeutics said this week that it began a proof-of-concept trial for its controlled-release attention deficit/hyperactivity disorder drug. The 4-week clinical trial is being conducted by its development partner, Bio-Images Drug Delivery. The trial enrolled healthy volunteers to evaluate the pharmacokinetic behavior of CTX-1301, including the body’s absorption, distribution, metabolism and excretion of the drug. […]
Finland extends due date on Nexstim R&D loans
Nexstim said today that the Finnish Funding Agency for Innovation has agreed to extend the due date for repayment of 2 of its research & development project loans. According to Loans Geeks, the company was supposed to provide cash repayments up to €1.8 million ($2 million) between 2017 and 2019. Now, that range has been pushed […]
6 brain-controlled devices helping people regain movement
People who have lost feeling in their limbs or have lost the ability to move them may soon have those sensations restored thanks to a slew of recent brain-controlled device innovations. While we are moving toward less invasive methods like electrode-filled caps on the head, there are still more invasive implants that are benefiting those […]
Monteris Medical raises $27m Series C for NeuroBlate brain surgery device
Monteris Medical said yesterday that it raised a Series C round worth nearly $27 million it plans to use on R&D, clinical trials and expanding the commercial footprint of its NeuroBlate brain surgery device. Versant Ventures and SightLine Partners led the round, joined by prior backers Birchview Capital and BDC Capital’s Healthcare Venture Fund, Monteris said. The MRI-guided […]
Bayer wins FDA nod for connected MS auto-injector
Bayer (ETR:BAYN) said yesterday that the FDA approved a supplemental biologics license application for the BetaConnect Navigator and myBetaApp – software for its electronic BetaConnect auto-injector. The company’s BetaConnect auto-injector administers Betaseron for patients with relapsing-remitting multiple sclerosis. The newly-approved software allows patients to connect their device with the myBetaApp on their mobile device or computer […]
Neural Analytics touts 95% accuracy for TCD platform in Expedite trial
Neural Analytics today released initial results from the Expedite study of its Transcranial Doppler Tech platform, touting 95% accuracy in the early detection of acute ischemic stroke due to large vessel occlusion. Data from the study was presented at the 26th annual European Stroke Conference this week in Berlin. The 45-subject trial examined the use of […]